Comparing Immunomedics (IMMU) and Oramed Pharmaceuticals (ORMP)
Immunomedics (NASDAQ: IMMU) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.
Valuation and Earnings
This table compares Immunomedics and Oramed Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Immunomedics||$3.09 million||386.06||-$71.33 million||($1.43)||-7.50|
|Oramed Pharmaceuticals||$2.19 million||60.34||-$11.45 million||($0.96)||-10.33|
Oramed Pharmaceuticals has higher revenue, but lower earnings than Immunomedics. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunomedics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Immunomedics has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.
This table compares Immunomedics and Oramed Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
58.5% of Immunomedics shares are held by institutional investors. Comparatively, 1.3% of Oramed Pharmaceuticals shares are held by institutional investors. 6.6% of Immunomedics shares are held by insiders. Comparatively, 27.5% of Oramed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a breakdown of current recommendations and price targets for Immunomedics and Oramed Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Immunomedics currently has a consensus price target of $15.50, suggesting a potential upside of 44.59%. Oramed Pharmaceuticals has a consensus price target of $25.00, suggesting a potential upside of 152.02%. Given Oramed Pharmaceuticals’ higher probable upside, analysts plainly believe Oramed Pharmaceuticals is more favorable than Immunomedics.
Immunomedics Company Profile
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.
Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.